FASEB J. Uncover Your Biological Pathway
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MURPHY, K. L.
Right arrow Articles by ROSEN, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MURPHY, K. L.
Right arrow Articles by ROSEN, J. M.
(The FASEB Journal. 2000;14:2291-2302.)
© 2000 FASEB

A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model

KRISTEN L. MURPHY*,{dagger}, ANDREW P. DENNIS{dagger} and JEFFREY M. ROSEN{dagger}1

* Program in Cell and Molecular Biology and
{dagger} Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA

1Correspondence: Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. E-mail: jrosen{at}bcm.tmc.edu

Approximately 40% of human breast cancers contain alterations in the tumor suppressor p53. The p53 172R-H gain-of-function mutant (equivalent to the common 175R-H human breast cancer mutant) has been shown to promote aneuploidy and tumorigenesis in the mammary gland in transgenic mice and may affect genomic stability in part by causing centrosome abnormalities. The precise mechanism of action of these gain-of-function mutants is not well understood, and has been studied primarily in fibroblast cell lines. A novel p53-null mouse mammary epithelial cell line developed from p53-null mice has been used in adenovirus-mediated transient transfection experiments to study the properties of this p53 mutant. Marked centrosome amplification and an increased frequency of aberrant mitoses were observed within 72 h of introduction of p53 172R-H. However, few cells with aberrant centrosome numbers were observed in cells stably expressing the p53 172R-H mutant. Furthermore, stable expression of this p53 mutant reduced both basal and DNA damage-induced apoptosis. This result may be mediated in part through abrogation of p73 function. The p53 172R-H mutant, therefore, appears to influence tumorigenesis at the molecular level in two distinct ways: promoting the development of aneuploidy in cells while also altering their apoptotic response after DNA damage.—Murphy, K. L., Dennis, A. P., Rosen, J. M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model.


Key Words: mutant p53 • apoptosis • aneuploidy • centrosome abnormalities




This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Perez-Losada, J.-H. Mao, and A. Balmain
Control of Genomic Instability and Epithelial Tumor Development by the p53-Fbxw7/Cdc4 Pathway
Cancer Res., August 1, 2005; 65(15): 6488 - 6492.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Kawamura, H. Izumi, Z. Ma, R. Ikeda, M. Moriyama, T. Tanaka, T. Nojima, L. S. Levin, K. Fujikawa-Yamamoto, K. Suzuki, et al.
Induction of Centrosome Amplification and Chromosome Instability in Human Bladder Cancer Cells by p53 Mutation and Cyclin E Overexpression
Cancer Res., July 15, 2004; 64(14): 4800 - 4809.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
I. Hernandez, L. A. Maddison, Y. Wei, F. DeMayo, T. Petras, B. Li, J. R. Gingrich, J. M. Rosen, and N. M. Greenberg
Prostate-Specific Expression of p53R172L Differentially Regulates p21, Bax, and mdm2 to Inhibit Prostate Cancer Progression and Prolong Survival
Mol. Cancer Res., December 1, 2003; 1(14): 1036 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke
From the Cover: Prospective identification of tumorigenic breast cancer cells
PNAS, April 1, 2003; 100(7): 3983 - 3988.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Strano, G. Fontemaggi, A. Costanzo, M. G. Rizzo, O. Monti, A. Baccarini, G. Del Sal, M. Levrero, A. Sacchi, M. Oren, et al.
Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities
J. Biol. Chem., May 17, 2002; 277(21): 18817 - 18826.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Iwanaga and K.-T. Jeang
Expression of Mitotic Spindle Checkpoint Protein hsMAD1 Correlates with Cellular Proliferation and Is Activated by a Gain-of-Function p53 Mutant
Cancer Res., May 1, 2002; 62(9): 2618 - 2624.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. J. Marrogi, M. A. Khan, H. E. van Gijssel, J. A. Welsh, H. Rahim, A. J. Demetris, K. V. Kowdley, S. P. Hussain, J. Nair, H. Bartsch, et al.
Oxidative Stress and p53 Mutations in the Carcinogenesis of Iron Overload-Associated Hepatocellular Carcinoma
J Natl Cancer Inst, November 7, 2001; 93(21): 1652 - 1655.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by The Federation of American Societies for Experimental Biology.